Grupo International Inc is categorized under Pharmaceutical Manufacturing Plant Construction in San Diego, CA and active since 2010.
Grupo International Inc was established in 2010, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Pharmaceutical Manufacturing Plant Construction business, which does work in the B2B market, and is classified as a Pharmaceutical Manufacturing Plant Construction, under code number 236220 by the NAICS.
If you are seeking more information, feel free to contact at the company’s single location by writing to 1909 Palm Avenue, San Diego, California CA 92154 or by phoning (619) 308-7943. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Grupo International Inc |
| Address: | 1909 Palm Avenue, San Diego, California 92154 |
| Phone Number: | (619) 308-7943 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2010 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Pharmaceutical Manufacturing Plant Construction |
| SIC Code: | 1541 |
| NAICS Code: | 236220 |
| Share This Business: |
Grupo International Inc was started in 2010 to provide professional Pharmaceutical Manufacturing Plant Construction under the SIC code 1541 and NAICS code 236220. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact for inquiries that concern Grupo International Inc by calling the company number (619) 308-7943, as your correspondence is most welcome. Additionally, the physical location of the single location of Grupo International Inc can be found at the coordinates 32.583608,-117.092402 as well as the street address 1909 Palm Avenue in San Diego, California 92154.
For its online presence, you may visit Grupo International Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.